))
Developing Treatments
Manage episode 312495041 series 3236617
Content provided by David Cunnington and SCN2A Australia. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by David Cunnington and SCN2A Australia or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Taking a treatment from the laboratory in to clinical trials and then to becoming available for use is a complex and expensive process. We talk with Dr Kiran Reddy, President and CEO of Praxis Precision Medicines, about the plans for the RC-222 treatment program with the eventual goal of having a treatment available for SCN2A gain-of-function epilepsies.
Hosted by Kris Pierce and David Cunnington, parents of Will, who has SCN2A.
Leave a review and subscribe via Apple Podcasts.
You can also find SCN2A Insights on Spotify, and Google Podcasts or in your podcast app
Links:
- Praxis Precision Medicines
- Antisense oligonucleotide therapy for gain-of-function SCN2A epilepsies
- Natural History Study – podcast on SCN2A natural history study
See omnystudio.com/listener for privacy information.
28 episodes
Share
